Transaction #30112 · Form 4 · 0001813798-26-000021
Vaxcyte, Inc. · Exercise / conversion · Common Stock
Vaxcyte, Inc. · Transacted October 1, 2026 · Filed October 2, 2026
What does this filing report?
An SEC Form 4 filing for Vaxcyte, Inc. records an exercise / conversion involving Common Stock on October 1, 2026. The reported quantity was 2,250. The filing date is October 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vaxcyte, Inc.
- Company CIK
- 0001649094
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 2,250
- Reported price
- 5.35
- Reference value
- 12,037.5
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 147,685
- Ownership description
- Not reported
- SEC acceptance time
- Oct 2, 2026, 4:05 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Wassil Jim ↗
EVP, Chief Scientific Ofc, COO
CIK 0001813798
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F2
- The price reported is a weighted-average price. The shares were sold at prices ranging from $56.065 to $56.955. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3
- The price reported is a weighted-average price. The shares were sold at prices ranging from $57.09 to $57.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4
- Stock Option is fully vested and exercisable.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.